China
Africa
Explore chapters and articles related to this topic
Medical Applications
Published in Suresh C. Ameta, Rakshit Ameta, Garima Ameta, Sonochemistry, 2018
Rosenthal et al. (2004) reviewed sonodynamic therapy (SDT) which deals with the enhancement of cytotoxic activities of sonosensitizers in the studies of cells in tumour-bearing animals, as the ultrasound energy can be directly focussed on malignancy sites present deep in tissues and can be used to activate a preloaded sonosensitizer. Probable mechanism of SDT include the formation of radicals derived by sonosensitizer, making the cell more susceptible to ultrasound-assisted drug transport across the cell membrane. This is also termed as sonoporation.
A Perspective of Ultrasound-Related Micro/Nano Cancer Therapy
Published in Hala Gali-Muhtasib, Racha Chouaib, Nanoparticle Drug Delivery Systems for Cancer Treatment, 2020
Tingting Zheng, Yun Chen, Jiao Peng, Yu Shi, Jun Zhang, Haitao Xiao, Xiangmei Chen, Yongcan Huang, Tao Pei, Zhuxia Zhang, Xue Zhang, Xiaohe Bai, Li Liu, Jinrui Wang
Sonodynamic therapy (SDT) is one of the most important ultrasound-related cancer treatments [187–189]. Compared with photodynamic therapy (PDT), acoustic waves can penetrate deeper into tissues than laser; therefore SDT has attracted more attention in preclinical studies. There are three key points to trigger SDT. These include ultrasound, sonosensitizers, and oxygen molecules [13, 187, 190, 191].
Medical Applications of Ultrasonic Energy
Published in Dale Ensminger, Leonard J. Bond, Ultrasonics, 2011
Dale Ensminger, Leonard J. Bond
Sonodynamic therapy is the term used for ultrasound-dependent enhancement of cyotoxic activities of certain sonosensitive compounds that interact in vitro and in tumor-bearing animals. Ultrasound, usually at 20 kHz or higher frequencies, is delivered as focused energy on malignancy sites buried deep in tissues to activate preloaded sonosensitive compounds.
Water-soluble and amphiphilic phospholipid copolymers having 2-methacryloyloxyethyl phosphorylcholine units for the solubilization of bioactive compounds
Published in Journal of Biomaterials Science, Polymer Edition, 2018
Kazuhiko Ishihara, Mingwei Mu, Tomohiro Konno
Recently, a new approach, called sonodynamic therapy, has been developed, whereby the activation of photosensitizers is carried out by ultrasound irradiation to improve the minimal tissue-penetrating ability of light in photodynamic therapy. Ultrasound can penetrate deeply into tissues and can be focused into a small tumor region to activate the sonosensitizer. Although ultrasound is expected to improve the tumoricidal effects of PDT, skin problems caused by the photosensitizers still remain. Hachimine et al. synthesized a new porphyrin derivative as a sonosensitizer, namely the 13,17-bis-(1-carboxyethyl)-8-[2-(2,4-dichlorophenyl-hydrazono)ethylidene]-3-ethenyl-7-hydroxy-2,7,12,18-tetramethylchlorin, disodium salt] (DCPH-P-Na(I)). PMB was used as DCPH-P-Na solubilizer to prepare injectable aqueous solutions (DCPH-P-Na(I)/PMB complex) [43]. The pharmacological effects of the DCPH-P-Na(I)/PMB complex were confirmed. The researchers concluded that sonodynamic therapy with the DCPH-P-Na(I)/PMB complex can be useful for the clinical treatment of cancers located deep in the human body, without inducing skin sensitivity, which tends to be a major side-effect of photosensitizers.